Home Featured Page 287

Featured

Latest

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

The Problem and Paradox of Bad Trips – Part 1

Champignon Brands to Restate Financial Statements and MD&A has Prepared CSE...

Interview With Payton Nyquvest

Charley Wininger Hopes to Normalize MDMA With New Book ‘Listening to...

How Past Stigma and Recreational Use Are Slowing Psychedelic Science

John C. Lilly: Father of LSD In the Sensory Deprivation Tank

Psyched Wellness Closes $6,603,000 Bought Deal Private Placement

Revive Therapeutics Acquires Unique Psilocybin Assets

PharmaTher Announces Sale of Psilocybin Program

Video Roundtable: The Future of Ketamine Therapy

1...286287288...299 Page 287 of 299

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

The Problem and Paradox of Bad Trips – Part 1

Champignon Brands to Restate Financial Statements and MD&A has Prepared CSE...

Interview With Payton Nyquvest

Charley Wininger Hopes to Normalize MDMA With New Book ‘Listening to...

How Past Stigma and Recreational Use Are Slowing Psychedelic Science

John C. Lilly: Father of LSD In the Sensory Deprivation Tank

Psyched Wellness Closes $6,603,000 Bought Deal Private Placement

Revive Therapeutics Acquires Unique Psilocybin Assets

PharmaTher Announces Sale of Psilocybin Program

Video Roundtable: The Future of Ketamine Therapy

EDITOR PICKS

Megan Portnoy MS – Ontological Design, Psychedelic Spaces, and Integrating Rigor

The Psychedelic News Feed: October 6 – 12, 2025

Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY